6/13/2013

Amgen and Cytokinetics agreed to expand an existing licensing deal centered on the experimental heart failure drug omecamtiv mecarbil and related compounds to include the Japanese market. The expanded deal entitles Cytokinetics to $25 million in upfront payment and as much as $50 million in milestone fees plus sales royalties.

Related Summaries